Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis

Zhu, Lei; Sun, Jin; Ling, Wang; Li, Zhigang; Wang, Lei; Li, Zhibin

doi:10.3389/fphar.2019.00962

Cited by 35 publications

(30 citation statements)

References 42 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic value of PD-L1 was also investigated in previous studies using a meta-analytic approach. A meta-analysis including 11 studies demonstrated that PD-L1 overexpression was a predictor of worse survival outcomes in bladder cancer (29). Furthermore, high PD-L1 was significantly correlated with later tumor stages (OR = 3.9, 95%CI = 2.71.5.61, p < 0.001) and distant metastases (OR = 2.5, 95%CI = 1.22.5.1, p = 0.012) in bladder cancer (29).…”

Section: Discussionmentioning

confidence: 99%

“…A meta-analysis including 11 studies demonstrated that PD-L1 overexpression was a predictor of worse survival outcomes in bladder cancer (29). Furthermore, high PD-L1 was significantly correlated with later tumor stages (OR = 3.9, 95%CI = 2.71.5.61, p < 0.001) and distant metastases (OR = 2.5, 95%CI = 1.22.5.1, p = 0.012) in bladder cancer (29). Another meta-analysis on non-small cell lung cancer (NSCLC) showed that PD-L1 expression was significantly associated with histology type, differentiation, and tumor stage, whereas the relationship between PD-L1 expression and OS was not statistically significant (p = 0.863) (30).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

Lü¹,

Li²,

Luo³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: A series of studies have explored the prognostic value of programmed death-ligand 1 (PD-L1) in patients with endometrial cancer (EC); however, the results are controversial. Therefore, this meta-analysis was performed to estimate the associations between PD-L1 expression and the prognosis and clinicopathological features of EC. Methods: A comprehensive literature search of PubMed, Web of Science, and Embase was conducted up until September 06, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were computed using the random-effects model (REM) or fixed-effects model (FEM). Odds ratios (ORs) and 95% CIs were calculated to evaluate the relationship between PD-L1 and clinicopathological factors. Results: A total of 9 studies with 1,615 patients were included in the meta-analysis. The combined data showed that high expression of PD-L1 was not significantly correlated with OS (HR = 1.20, 95% CI = 0.41-3.52, p = 0.737) or PFS (HR = 1.12, 95% CI = 0.50-2.54, p = 0.778) in EC. In addition, PD-L1 expression was significantly associated with poor differentiation (OR = 2.82, 95% CI = 1.96-4.06, P < 0.001) and advanced stage (OR = 1.71, 95% CI = 1.12-2.60, p = 0.013). Conclusion: This meta-analysis suggests that PD-L1 expression is not associated with poor prognosis in patients with EC. However, PD-L1 expression is positively correlated with poor differentiation and advanced tumor stage in EC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

Lü¹,

Li²,

Luo³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…But, PD-L1 expression on clinical prognosis is poorly defined in UC. Some studies have suggested that PD-L1 overexpression was correlated with poor prognosis in bladder cancer (25)(26)(27). On the other hand, some studies reported that PD-L1 expression has no correlation with clinical outcome in UC (28,29).…”

mentioning

confidence: 99%

PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype

et al. 2020

View full text Add to dashboard Cite

Urothelial carcinoma (UC) is the most common histologic type of urinary bladder cancer, and muscle-invasive UC shows aggressive behaviors. Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) blockades have been approved as standard treatments for patients with advanced stage UC. A total of 166 muscle-invasive urinary bladder cancer (MIBC) patients, who underwent transurethral resection of the bladder or cystectomy from 2004 to 2010 were included. We evaluated PD-L1 expression by the SP142 and SP263 assays and classified the cases “positive” or “negative” according to the manufacturer’s recommendations. We performed immunohistochemistry (IHC) for cytokeratin (CK) 5/6, CK14, GATA3, FOXA1, and CK20 and classified samples as Basal-Squamous-like (BASQ) or non-BASQ subtype. The overall concordance rate for PD-L1 expression is 91.6% (152/166) (kappa = 0.732). The SP142 assay showed 15.1% positivity; the SP263 assay showed 23.5%. The high positivity in the SP142 and SP263 assay was significantly correlated with positive CK5/6, CK14 expression, negative GATA3, FOXA1, and CK20 expression. Classification according to IHC expression resulted in 12.0% (20/166) of samples being classified as BASQ subtype and 88.0% (146/166) of samples being classified as non-BASQ subtype. High positivity in the SP142 and SP263 assay was significantly correlated with the BASQ subtype (p < 0.001, both). Our study is the first to analyze the association of immunohistochemically defined BASQ and non-BASQ subtypes with two PD-L1 assays in MIBC. In conclusion, we revealed that a high PD-L1 positive rate in all PD-L1 assays was significantly associated with the BASQ-subtype, and these results suggest that the BASQ classification may be important to apply the PD-1/PD-L1 blockades in MIBC.

show abstract

“…As an immunosuppressive molecule, PD-L1 can inhibit the activity of T cells through a variety of complex signaling pathways, thus promoting tumor progression [ 17 – 19 ]. The relationship between the expression of PD-L1 and the prognosis of different cancer patients has been controversial.…”

Section: Discussionmentioning

confidence: 99%

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer

Chao

Wang

2021

Cancer Cell Int

View full text Add to dashboard Cite

Background CKLF Like MARVEL Transmembrane Domain Containing 6 (CMTM6) is involved in the epigenetic regulation of genes and tumorigenesis. Programmed cell death ligand 1 (PD-L1) is closely related to the prognosis of some human cancers. CMTM6 is a key regulator of PD-L1 in many cancers. The purpose of this study was to investigate the expressions of these proteins in gastric cancer and the correlations with clinicopathological features and survival. Methods The expression levels of CMTM6 and PD-L1 were examined in 185 gastric cancer specimens using immunohistochemistry, quantitative real-time PCR and Western blot. Immunofluorescence was used to examine the localizations of CMTM6 and PD-L1. Chi-square test was used to analyze the relationship between CMTM6 and PD-L1 expressions and clinicopathological characteristics. Kaplan–Meier method and log-rank test were used to analyze the survival data of patients. Results The positive expression rates of CMTM6 and PD-L1 in gastric cancers were 78.38% (145/185) and 75.68% (140/185), respectively. CMTM6 and PD-L1 were both mainly expressed in the cell membrane and nucleus of gastric cancer tumor cells. High expression of CMTM6 and PD-L1 was correlated with Borrmann type (P < 0.001), N stage (P = 0.002), peritoneal metastasis (P = 0.007) and TNM stage (P = 0.038). CMTM6 and PD-L1 expression in gastric cancer tissues showed a positive correlation (Pearson’s coefficient test, r = 0.260; P < 0.001). CMTM6 may positively regulate PD-L1 expression. High expression of CMTM6 was correlated with poor prognosis of gastric cancer patients (HR = 1.668; 95% CI = 1.032–2.695; P = 0.037). High expression of both CMTM6 and PD-L1 may be an independent factor for overall survival (HR = 1.554; 95% CI = 1.011–2.389; P = 0.044). Conclusion The combined detection of CMTM6 and PD-L1 may be used as an indicator for judging the prognosis of gastric cancer patients.

show abstract

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis

Cited by 35 publications

References 42 publications

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer

Contact Info

Product

Resources

About